Novartis Says Afinitor More Than Doubles Progression Free Survival In Patients With Advanced Pancreatic NET – Update
Thursday, Swiss drug giant Novartis AG (NVS) said that in a late-stage trial, its kidney cancer drug Everolimus, sold under the brand name Afinitor, plus best supportive care, more than doubled progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors. The results of the trial were presented at the 12th World Congress on Gastrointestinal …

Read more on RTT News